In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum

Basit Öğe Kaydı
dc.authorid55857860900
dc.authorid23502381000
dc.authorid6603903192
dc.contributor.authorTürkeş C.
dc.contributor.authorSöyüt H.
dc.contributor.authorBeydemir S.
dc.date.accessioned20.04.201910:49:12
dc.date.accessioned2019-04-20T21:43:39Z
dc.date.available20.04.201910:49:12
dc.date.available2019-04-20T21:43:39Z
dc.date.issued2016
dc.departmentBayburt Üniversitesien_US
dc.description.abstractIn this study, we investigated the effects of the drugs, palonosetron hydrochloride, bevacizumab and cyclophosphamide, on human serum paraoxonase-I (hPON1) enzyme activity in in vitro conditions. The enzyme was purified ~231-fold with 34.2% yield by using ammonium sulphate precipitation, DEAE-Sephadex A-50 ion-exchange chromatography and Sephadex G-200 gel-filtration chromatography from human serum. hPON1 exhibited a single protein band on the SDS polyacrylamide gel electrophoresis. The inhibition studies were performed on paraoxonase activity of palonosetron hydrochloride, bevacizumab and cyclophosphamide. Ki constants were found as 0.033 ± 0.001, 0.054 ± 0.003 mM and 3.419 ± 0.518 mM, respectively. Compared to the inhibition rates of the drugs, palonosetron hydrochloride has the maximum inhibition rate. However, inhibition mechanisms of the drugs were determined as noncompetitive by Lineweaver-Burk curves. © 2016 Elsevier B.V.en_US
dc.identifier.doi10.1016/j.etap.2015.11.024
dc.identifier.endpage257
dc.identifier.issn1382-6689
dc.identifier.pmid26915059en_US
dc.identifier.scopus2-s2.0-84958974418en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage252
dc.identifier.urihttps://dx.doi.org/10.1016/j.etap.2015.11.024
dc.identifier.urihttps://hdl.handle.net/20.500.12403/636
dc.identifier.volume42
dc.identifier.wosWOS:000372763600033en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier B.V.
dc.relation.ispartofEnvironmental Toxicology and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumab
dc.subjectCyclophosphamide
dc.subjectInhibition
dc.subjectPalonosetron hydrochloride
dc.subjectParaoxonase
dc.subjectaryldialkylphosphatase
dc.subjectaryldialkylphosphatase 1
dc.subjectbevacizumab
dc.subjectcyclophosphamide
dc.subjectmessenger RNA
dc.subjectpalonosetron
dc.subjectaryldialkylphosphatase
dc.subjectbevacizumab
dc.subjectcyclophosphamide
dc.subjectDEAE-Sephadex A-50
dc.subjectdextran
dc.subjectdiethylaminoethyldextran
dc.subjectenzyme inhibitor
dc.subjectisoquinoline derivative
dc.subjectpalonosetron
dc.subjectquinuclidine derivative
dc.subjectsephadex
dc.subjectArticle
dc.subjectblood level
dc.subjectcontrolled study
dc.subjectdrug mechanism
dc.subjectenzyme activity
dc.subjectenzyme assay
dc.subjectenzyme inhibition
dc.subjectenzyme purification
dc.subjectgel filtration chromatography
dc.subjectgene expression
dc.subjecthuman
dc.subjectIC50
dc.subjectin vitro study
dc.subjection exchange chromatography
dc.subjectmolecular dynamics
dc.subjectpolyacrylamide gel electrophoresis
dc.subjectpriority journal
dc.subjectanalogs and derivatives
dc.subjectmetabolism
dc.subjectsize exclusion chromatography
dc.subjectAryldialkylphosphatase
dc.subjectBevacizumab
dc.subjectChromatography, Gel
dc.subjectCyclophosphamide
dc.subjectDEAE-Dextran
dc.subjectDextrans
dc.subjectEnzyme Inhibitors
dc.subjectHumans
dc.subjectIsoquinolines
dc.subjectQuinuclidines
dc.subjectBevacizumab
dc.subjectCyclophosphamide
dc.subjectInhibition
dc.subjectPalonosetron hydrochloride
dc.subjectParaoxonase
dc.subjectaryldialkylphosphatase
dc.subjectaryldialkylphosphatase 1
dc.subjectbevacizumab
dc.subjectcyclophosphamide
dc.subjectmessenger RNA
dc.subjectpalonosetron
dc.subjectaryldialkylphosphatase
dc.subjectbevacizumab
dc.subjectcyclophosphamide
dc.subjectDEAE-Sephadex A-50
dc.subjectdextran
dc.subjectdiethylaminoethyldextran
dc.subjectenzyme inhibitor
dc.subjectisoquinoline derivative
dc.subjectpalonosetron
dc.subjectquinuclidine derivative
dc.subjectsephadex
dc.subjectArticle
dc.subjectblood level
dc.subjectcontrolled study
dc.subjectdrug mechanism
dc.subjectenzyme activity
dc.subjectenzyme assay
dc.subjectenzyme inhibition
dc.subjectenzyme purification
dc.subjectgel filtration chromatography
dc.subjectgene expression
dc.subjecthuman
dc.subjectIC50
dc.subjectin vitro study
dc.subjection exchange chromatography
dc.subjectmolecular dynamics
dc.subjectpolyacrylamide gel electrophoresis
dc.subjectpriority journal
dc.subjectanalogs and derivatives
dc.subjectmetabolism
dc.subjectsize exclusion chromatography
dc.subjectAryldialkylphosphatase
dc.subjectBevacizumab
dc.subjectChromatography, Gel
dc.subjectCyclophosphamide
dc.subjectDEAE-Dextran
dc.subjectDextrans
dc.subjectEnzyme Inhibitors
dc.subjectHumans
dc.subjectIsoquinolines
dc.subjectQuinuclidines
dc.titleIn vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serumen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu